Los Angeles, CA, USA, May 5th, 2022 – ImaginAb, Inc., a market leading global biotechnology company focused on developing next generation ImmunoPET imaging agents and therapeutic radiopharmaceuticals (RPT), is pleased to announce it has signed a new multi-year, non-exclusive supply agreement with Genmab A/S, an international biotechnology company. Read more…
Precirix NV, a clinical-stage biotechnology company developing precision radiopharmaceuticals in oncology, today announces the closing of a EUR 80m Series B financing round led by new investors INKEF Capital, Jeito Capital and Forbion as co-leads. Read more
Promising non-clinical results support Phase 1 clinical study in recurrent GBM Commitment to ensuring I-123 PARPi is available to treat the unmet medical need of patients diagnosed with primary and recurrent GBM LONDON, UK, 10 February 2022 – Theragnostics, which is developing radiopharmaceuticals for imaging and treatment of cancer, today announces that its novel I-123 […]
